The content is available as a PDF (43.9 KB).
Bibliografía
- 1.López-Rodríguez I., Castro-Beiras A., Asensi A., Bacariza F., Rábade J.M., Núñez J. Normas básicas de manejo de la insuficiencia cardíaca en atención primaria. Aten Primaria. 1999;24:289–294. [PubMed] [Google Scholar]
- 2.Weber K.T. Aldosterone and spironolactone in heart failure. N Engl J Med. 1999;341:753–754. doi: 10.1056/NEJM199909023411009. [DOI] [PubMed] [Google Scholar]
- 3.The Rales Investigators Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]) Am J Cardiol. 1996;78:902–907. doi: 10.1016/s0002-9149(96)00465-1. [DOI] [PubMed] [Google Scholar]
- 4.Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Pérez A. The effect of spironolactone on morbidity and mortality in patients with severe hearyt failure. N Engl J Med. 1999;341:709–717. doi: 10.1056/NEJM199909023411001. [DOI] [PubMed] [Google Scholar]
- 5.Brotons C., Moral I., Ribera A., Pérez G., Cascant P., Bastius M., Permanyer-Miralda G. Tendencias de la morbimortalidad por insuficiencia cardíaca en Cataluña. Rev Esp Cardiol. 1998;51:972–976. doi: 10.1016/s0300-8932(98)74849-3. [DOI] [PubMed] [Google Scholar]
- 6.Antoñanzas Villar F., Antón Botella F., Juárez Castello C.A., Echevarría Echarri L. Costes de la insuficiencia cardíaca crónica en España. An Med Intern (Madrid) 1997;14:9–14. [PubMed] [Google Scholar]